Literature DB >> 7435537

The distribution of lipopolysaccharide in normocomplementemic and C3-depleted rabbits and rhesus monkeys.

J C Mathison, R J Ulevitch, J R Fletcher, C G Cochrane.   

Abstract

To examine the role of complement (C3) in determining the fate of lipopolysaccharide (LPS) in vivo, the distribution of LPS was studied in normocomplementemic (NC) and C3-depleted animals (pretreated with cobra venom factor [CoF]) after intravenous injection of highly purified, radioiodinated Salmonella minnesota R595 LPS. After injection of a lethal (250 micrograms) or nonlethal (5 micrograms) dose of LPS in NC and CoF rabbits and a lethal (5 mg/kg) dose of LPS in rhesus monkeys, the LPS disappeared from blood in a biphasic manner. In all cases, a substantial portion of the dose was removed from blood in an initial disappearance phase (t1/2 < 15 minutes), which, in some cases, was accelerated in CoF-treated animals. LPS remaining in blood beyond 30 minutes persisted with a much increased half-life (> 5 hours). Liver contained the major portion (40%) of tissue-bound LPS (determined by use of 131I-BSA blood marker) in animals killed 3--5 hours after injection. The distribution of LPS in rabbits was found to be dose-indpendent and only minimally changed by prior depletion of C3. In addition, the tissue distribution and cellular localization of LPS in monkeys was similar to that we have reported previously for R595 LPS in NC rabbits and was not substantially changed by prior CoF treatment. These results indicate that binding of C3 to intravenously injected LPS is not required for the initial rapid disappearance from blood. Further, the uptake of LPS by cellular targets, notably the hepatic macrophages (Kupffer cells), is not altered by in vivo decomplementation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7435537      PMCID: PMC1903612     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  Protection against lethality of E. coli endotoxin with "O" antiserum.

Authors:  W J Tate; H Douglas; A I Braude; W W Wells
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

3.  The preparation and characterization of a radioiodinated bacterial lipopolysaccharide.

Authors:  R J Ulevitch
Journal:  Immunochemistry       Date:  1978-03

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

5.  Endotoxin-induced regional circulatory changes in the unanesthetized monkey.

Authors:  F Wyler; R P Forsyth; A S Nies; J M Neutze; K L Melmon
Journal:  Circ Res       Date:  1969-06       Impact factor: 17.367

6.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

7.  The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits.

Authors:  J C Mathison; R J Ulevitch
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

8.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

9.  The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey.

Authors:  R J Ulevitch; C G Cochrane; K Bangs; C M Herman; J R Fletcher; C L Rice
Journal:  Am J Pathol       Date:  1978-07       Impact factor: 4.307

10.  Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.

Authors:  J O Shaw; M F Roberts; R J Ulevitch; P Henson; E A Dennis
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

View more
  8 in total

1.  Tumour necrosis factor alpha secretion in leporine endotoxaemia: role of the liver and effects of hepatic ischaemia.

Authors:  I L Badger; P Townsend; J A Buckels
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

2.  In vivo and in vitro studies of bacterial endotoxin-membrane interactions and the effects of membrane-active agents.

Authors:  M E Garnett; D V Godin; J M Tuchek
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

3.  Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture.

Authors:  G K Wollenberg; L E DeForge; G Bolgos; D G Remick
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

4.  Clearance and tissue distribution of intravenously injected Salmonella typhi polysaccharide in rabbits.

Authors:  A Isibasi; E Jimenez; J Kumate
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

5.  Psychoneuroimmune implications of type 2 diabetes: redux.

Authors:  Jason C O'Connor; Daniel R Johnson; Gregory G Freund
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

6.  Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.

Authors:  Theodore P Braun; Aaron J Grossberg; Stephanie M Krasnow; Peter R Levasseur; Marek Szumowski; Xin Xia Zhu; Julia E Maxson; J Gabriel Knoll; Anthony P Barnes; Daniel L Marks
Journal:  FASEB J       Date:  2013-06-03       Impact factor: 5.191

7.  Plasma acid phosphatase levels in endotoxaemia: modification by drugs and chemically detoxified endotoxins.

Authors:  D V Godin; J M Tuchek
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

Review 8.  The regulation of interleukin-6 implicates skeletal muscle as an integrative stress sensor and endocrine organ.

Authors:  Steven S Welc; Thomas L Clanton
Journal:  Exp Physiol       Date:  2012-08-31       Impact factor: 2.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.